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disease activity in RA, although the effect of the other antibiotics on disease activ-
ity should be examined.
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Background: Patients with rheumatoid arthritis (RA) experience an increased
frequency of heart failure with a preserved ejection fraction (HFpEF) (1). The treat-
ment of HFpEF is currently suboptimal. Elucidation of the underlying pathophysio-
logical mechanisms of HFpEF may provide potential targets for its management.
Diastolic dysfunction often precedes the progression to HFpEF (2). Abnormalities
in aortic function contribute to diastolic dysfunction in non-RA populations (3,4).
Objectives: The aim of this study was to determine whether impaired aortic func-
tion is associated with left ventricular diastolic dysfunction in RA.
Methods: Arterial function was determined by applanation tonometry using
SphygmoCor software and left ventricular diastolic function was assessed by
echocardiography in 176 patients with RA. Markers of arterial function included
carotid femoral pulse wave velocity (PWV), central systolic and pulse pressure,
pulse pressure amplification and the magnitude and timing of the forward and
reflected waves. Markers of diastolic function included the ratio of early-to-late
transmitral blood flow velocity (E/A), the ratio of E to the mean of the lateral and
septal wall myocardial tissue lengthening at the mitral annulus (e’)(E/e’) and the
septal and lateral e’. Relationships of comprehensively evaluated arterial function
with markers of LV diastolic function were determined in confounder adjusted mul-
tivariate regression models.
Results: The timing of the forward (Ft) and reflected (Rt) waves were each asso-
ciated with E/A (Ft: partial r=0.20, p=0.02; Rt: partial r=0.30, p=0.001) and Rt was
further associated with lateral e’ (partial r=0.36, p<0.0001) and septal e’ (partial
r=0.36, p<0.0001); PWV was associated with E/e’ (partial r=0.18; p=0.03).
Reflected wave timing was associated with two indices of impaired relaxation (E/
A<0.8: OR (95% CI)=0.51 (0.29-0.91), p=0.01; lateral e’<10: OR (95% CI)=0.43
(0.26-0.71), p=0.001); PWV was associated with an increased left ventricular fill-
ing pressure (E/e’>12: OR (95% CI)=1.58 (1.04-2.38), p=0.03).
Conclusions: Aortic stiffness and time to wave reflection are associated with
increased filling pressure and impaired relaxation of the left ventricle, respectively.
The development of diastolic dysfunction in RA may be partly mediated by
changes in large artery function.
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Background: Patients with Rheumatoid Arthritis (RA) may present with various
comorbidities resulting in worse treatment response.[1-2]
Objectives: To investigate the impact of selected comorbid diseases on RA out-
come with the aim of Disease Activity Score in 28 joints-C-Reactive Protein
(DAS28-CRP).
Methods: All our RA patients were included in this study. Patients’ demographics,
serology results and DAS28-CRP at the time of diagnosis and after 4 months of
treatment initiation were collected. Patients’ electronic hospital records were eval-
uated for a positive history of thyroid diseases, Diabetes Mellitus (DM), primary
hyperparathyroidism, vitamin B12 deficiency and presence of other diagnosed
autoimmune diseases.
Results: 1035 RA patients were included. 63.4% were female, mean of age 67.1
years, mean of disease duration 9.6 years, 58.6% rheumatoid factor positive and
51.3% anti-cyclic citrullinated peptide positive. The observed prevalence of thy-
roid diseases was 11.8%, DM 10.4%, primary hyperparathyroidism 2.8%, vitamin
B12 deficiency 5.8%, and other diagnosed autoimmune diseases 1.6%. There
were significant associations between presence of thyroid diseases and female
gender (p<0.001); DM and greater age (p<0.001); primary hyperparathyroidism
and longer disease duration (p=0.002); other diagnosed autoimmune diseases
and antinuclear antibody positivity (p<0.001). RA patients with thyroid diseases
(p=0.001) and other comorbid autoimmune diseases (p<0.001) had significantly
poorer initial response to the RA treatment compared to patients with isolated RA.
Univariate analyses revealed that age, presence of thyroid diseases, presence of
other diagnosed autoimmune diseases and DAS28-CRP at the time of diagnosis
were significantly associated with ΔDAS28-CRP. Additionally, multivariate analy-
sis demonstrated that ΔDAS28-CRP deterioration was significantly correlated to
the presence of thyroid diseases (unstandardized regression coefficient (standard
error);-0.188(0.088),p=0.030) and presence of other diagnosed autoimmune dis-
eases (-0.537(0.208),p=0.010). (table1)
Table 1. Univariate and multivariate analysis of risk factors for ΔDAS28-CRP.
Variables Univariate
analysis
Multivariate
analysis
Backward
analysis
Gender 0.028 (0.066) 0.058 (0.056)
Age 0.007 (0.002)** 0.003 (0.002)
Disease
duration
0.000 (0.003) - 0.003 (0.003)
IgM- rheumatoid
factor
-0.055 (0.065) 0.014 (0.068)
Anti-
cyclic
citrullinated
peptide
antibody
-0.098 (0.065) -0.041 (0.068)
Antinuclear
antibody
0.003 (0.086) -0.042 (0.067)
Presence of
Thyroid
diseases
-0.315 (0.098)** -0.188 (0.088)* -
0.160 (0.081)*
Presence of
Primary
Hyperparathyroidism-0.059 (0.193)0.008 (0.159)Presence of Diabetes Mellitus0.077 (0.104)-
0.023 (0.086)Presence of vitamin B12 deficiency0.102 (0.136)0.047 (0.112)Presence of
other diagnosed autoimmune diseases-0.895 (0.249)**-0.537 (0.208)*-0.565 (0.204)*Thyroid
stimulating hormone level0.013 (0.008)0.011 (0.007)DAS28-CRP at time of diagnosis0.724
(0.027)**0.711 (0.029)**0.715 (0.029)***P value <0.05, ** P value <0.005
Conclusions: RA patients are at increased risk of specific comorbidities with pos-
sible impact on the treatment outcome. The authors, therefore, recommend to do
periodical assessment of comorbidities to diagnose concurrent comorbid dis-
eases as early as possible.
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Background: Clinical pathway analysis is the process of characterizing clinical
activities in patients’ (pts) care. Little is known about the clinical pathways that pts
with rheumatoid arthritis (RA) follow after their diagnosis, and how treatment pat-
terns differ between such pathways.
Objectives: To identify and characterize distinct clinical pathways in the manage-
ment of incident RA pts and evaluate differences in treatment patterns.
Methods: A retrospective cohort study was conducted in RA pts identified using
electronic medical records of the Kaiser Permanente Southern California health
plan. Between 01/01/2007 and 31/12/2015, we identified adult pts (aged ≥18
years) who had at least two RA diagnoses within a 12-month period, a disease-
modifying antirheumatic drug (DMARD) prescription and laboratory test for anti-
citrullinated peptide antibody. Latent class analysis (LCA) method was applied to
identify ≥2 heterogeneous care pathways. RA-specific healthcare utilization dur-
ing the first year following the RA diagnosis was used as a marker of underlying
latent classes. We characterized the latent classes based on the distribution of
markers, co-morbidities and RA treatment patterns including switch, augmenta-
tion and discontinuation of DMARDs. Chi-square and F-tests were used to evalu-
ate differences between the classes.
Results: We identified 2843 incident RA pts. LCA indicated five latent classes
representing mutually exclusive pathways of managing pts with RA. Pts in Class 1
(low disease activity-low progression) had lowest RA office visits and labs to
detectinflammation with the highest DMARD discontinuation. Pts in Class 2 (low-
disease activity-moderate progression) were characterized by higher lab, imaging
and DMARD augmentation. Class 3 (moderate disease activity with pain) was
characterized by highest use of NSAIDs across any class. Pts in Class 4(high dis-
ease activity-moderate progression) were characterized by above-average RA
office visits and the highest corticosteroid use. Class 5(high disease activity-high
progression) had pts with the highest number of RAoffice visits, biologic DMARD
use, DMARD augmentation, DMARD switching and the lowest initial treatment
discontinuation.
Classification factors Class 1
n=367
Class 2
n=1105
Class 3
n=516
Class 4
n=616
Class 5
n=239
Total
N=2843
Age, years (mean)* 54 56 56 60 50 56
Co-morbidities, n (mean)* 0.7 0.9 0.7 1.0 0.6 0.8
Female, %* 76 78 80 72 74 76
Medicare/Medicaid, %* 22 30 26 37 10 28
Switch to new DMARD, %* 2 5 9 8 13 6
Augment initial DMARD, %
*
7 16 37 36 80 29
Discontinue initial DMARD,
%*
73 49 31 30 6 41
Mean predicted utilization
of select markers
RA office visits, mean
count
3 5 7 8 9 6
Traditional DMARD fills,
mean count
3 4 6 6 5 5
Biologic DMARD fills, mean
count
<0.01 0.01 0.02 0.04 6.5 0.56
NSAID fills, mean count 1 1 4 <0.5 2 1
Corticosteroid fills, mean
count
1 1 2 4 3 2
CT scans, % 9 13 19 28 17 17
MRI, % 5 8 15 13 16 11
RF lab, % 2 22 17 19 15 17
ESR lab, % 29 98 88 93 97 85
CRP lab, % 7 74 66 65 75 61
*Difference between classes are statistically significant; p<0.05
Conclusions: We identified five distinct classes/care pathways; these could be
used to identify care gaps, implement standardized care plans and guide quality
initiatives in the management of pts with RA.
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Background: Tofacitinib is anoral Janus kinase inhibitor for the treatment of rheu-
matoid arthritis (RA).
Objectives: This post hoc analysis aims to explore the efficacy of tofacitinib in
patients (pts) with RA based on their baseline (BL) body mass index (BMI).
Figure 1. ACR20/50/70 response rates at Month 6 for each treatment group stratified by
BMI category (FAS, NRI). *p<0.05; **p<0.001; ***p<0.0001 vs placebo. ACR, American
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